PEAK6 Investments’s Verve Therapeutics VERV Stock Holding History

PEAK6 Investments’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-18,000	Closed	-$239K	–	4877
2023 Q3	$239K	Buy	+18,000	New	+$290K	﹤0.01%	2954

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

PEAK6 Investments's VERV Position: Q4 2023 in Review

PEAK6 Investments sold out of Verve Therapeutics (VERV) in Q4 2023, closing a stake of 18,000 shares — an estimated $239K sold.

PEAK6 Investments first reported a position in VERV in Q3 2023 and held it in 1 quarter. The position peaked at $239K in Q3 2023. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

PEAK6 Investments reported no remaining Verve Therapeutics position as of Q4 2023 after selling out during the quarter.
PEAK6 Investments sold 18,000 Verve Therapeutics shares in Q4 2023, an estimated $239K.
PEAK6 Investments first reported a position in Verve Therapeutics in Q3 2023 and held it in 1 quarter.
PEAK6 Investments's Verve Therapeutics position peaked at $239K in Q3 2023.
157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on PEAK6 Investments's 13F filing for Q4 2023, filed 13 Feb 2024.